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Background: Microinvasive breast cancer is an uncommon pathological entity. Owing to the rarity of this
condition, its surgical axillary management and overall prognosis remain controversial.
Methods: A database was analysed to identify patients with microinvasive ductal carcinoma in situ (DCIS)
who had surgery for invasive breast cancer at the European Institute of Oncology, Milan, between 1998
and 2010. Women who had undergone axillary staging by sentinel lymph node biopsy were included in
the study.
Results: Of 257 women with microinvasive breast cancer who underwent sentinel lymph node biopsy
(SLNB), 226 (87⋅9 per cent) had negative sentinel lymph nodes (SLNs) and 31 had metastatic SLNs.
Twelve patients had isolated tumour cells (ITCs), 14 had micrometastases and five had macrometastases
in sentinel nodes. Axillary lymph node dissection was performed in 16 of the 31 patients with positive
SLNs. After a median follow-up of 11 years, only one regional first event was observed in the 15 patients
with positive SLNs who did not undergo axillary lymph node dissection. There were no regional first
events in the 16 patients with positive SLNs who had axillary dissection.
Conclusion: Good disease-free and overall survival were found in women with positive SLNs
and microinvasive DCIS. This study is in line with studies showing that SLNB in microinvasive DCIS may
not be useful, and supports the evidence that less surgery can provide the same level of overall survival
with better quality of life.
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Introduction
Microinvasive breast cancer is an uncommon pathological
entity, accounting for approximately 1 per cent of all breast
cancers1,2. The definition of microinvasive breast cancer
has varied over time3,4.
Recently, the definition of microinvasion, as given by the
seventh edition of the AJCC staging manual5, of extension
of cancer cells beyond the basement membrane into the
adjacent tissue with no focus more than 1mm in greatest
dimension, has gained common acceptance. As a result, the
term ‘T1mic’ has now been added to the TNM staging
system5,6.
Owing to the rarity of this condition, questions remain
regarding the surgical management of the axilla and the
overall prognosis of this entity. In the literature, a large
incidence spectrum of axillary metastasis is found. This
can be attributable to differing definitions of microinva-
sive ductal carcinoma in situ (DCIS) over the years and to
the varying techniques used to analyse the sentinel node.
These differences are probably responsible for the different
recommendations on how to manage the axilla in microin-
vasive DCIS7.
DCIS is a disease devoid of invasive behaviour and thus
without potential for spread to the axillary lymph nodes.
Current practice is to perform sentinel lymph node biopsy
(SLNB) only in selected patients with DCIS when there is
substantial risk of upgrade of the lesion at final pathology,
such as a mass lesion highly suggestive of invasive cancer
at imaging and physical examination, patients with a large
area of DCIS at imaging (5 cm or greater), or whenmastec-
tomy is indicated8. However, evidence for this recommen-
dation is inadequate because of the sparsity of data analysed
in the literature, also characterized by a lack of long-term
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follow-up studies and still subject to controversial scientific
analysis9.
If staging the axilla in DCIS is accepted globally in the
above conditions, what remains controversial is the real
value of staging the axilla with SLNB in microinvasive
DCIS4,6,7,10–31, as reviewed in Table 14,6,7,10–24,27–31. The
incidence of axillary metastasis in sentinel nodes varies
in studies from approximately 2 to 20 per cent. This is
probably due to the different pathological methods used
to examine the sentinel node, as well as differences in
the methodology used to section the breast tissue. Factors
correlated with axillary nodal positivity in women with
DCIS and microinvasive DCIS are younger age, size of
DCIS lesion, histological grade, receptor status, human
epidermal growth factor receptor (HER) 2 overexpression
and lymphovascular invasion6,23,25.
To contribute to a better understanding of this surgi-
cal aspect, as well as to the prognostic implications of
microinvasion, this retrospective observational study exam-
ined patients with microinvasive breast cancer who under-
went axillary staging via SLNB.
Methods
After institutional review board approval, a database
of patients who underwent surgery for invasive breast
cancer at the European Institute of Oncology, Milan,
Italy, between 1998 and 2010 was analysed, and patients
with microinvasive DCIS were identified. Patients who
did not undergo axillary surgery were excluded, and the
remaining patients with microinvasive breast cancer who
had undergone axillary staging by SLNB were included
in the analysis.
Sentinel lymph node (SLN) identification was usually
performed using a radiocolloid technique (99mTc-labelled
colloidal particles of human albumin). Intraoperative
lymph node analysis was conducted using haematoxylin
and eosin-stained sections, when necessary aided by
immunohistochemical staining, as has been reported
previously32.
Based on AJCC classification criteria5, axillary lymph
node metastases were defined as follows: macrometastases
(larger than 2⋅0mm), micrometastases (0⋅2–2⋅0mm) or
isolated tumour cells (ITCs) (smaller than 0⋅2mm). Sys-
temic adjuvant therapy was recommended according to the
contemporary St Gallen treatment guidelines33–37.
The following parameters were used in the analysis:
clinical (year of surgery, age, menopausal status), pathol-
ogy (tumour histology, tumour grade, tumour subtype)
and type of treatment (local or systemic). Long-term
outcomes were studied via follow-up data recording the
first recurrence events, classified as local (ipsilateral breast
and chest), regional (ipsilateral axillary or supraclavicular
lymph nodes), distant metastasis, contralateral breast can-
cer, other primary tumour and death as the first-reported
event.
Statistical analysis
Demographic and clinical characteristics of the study sam-
ple were analysed using descriptive statistics. The associ-
ation between SLN status, and demographic and clinical
variables was evaluated using the χ2 test. Cumulative inci-
dences of the first observed relapse (categorized as local
recurrence, regional recurrence or distant metastasis) were
assessed from the date of surgery to the date of event. In
case of no event, the observation was censored at the last
follow-up visit. Cumulative incidence functions were esti-
mated according to the method described by Kalbfleisch
and Prentice38, taking into account the competing causes
of relapse. Gray’s test39 was used to assess cumulative inci-
dence differences between groups.
Overall survival (OS) was defined as the time from date
of surgery to date of death from any cause; disease-free
survival (DFS) was defined, according to standardized def-
initions for efficacy end points (STEEP) criteria40, as the
time from surgery to events such as relapse (including ipsi-
lateral breast tumour recurrence), appearance of a second
primary cancer (including contralateral breast cancer) or
death, whichever occurred first. OS and DFS curves were
estimated using the Kaplan–Meier method, and the log
rank test was used to assess differences between groups.
Median follow-up was calculated using the reverse
Kaplan–Meier method41. All analyses were performed
using SAS® software version 9⋅4 (SAS Institute, Cary,
North Carolina, USA). All statistical tests were two-sided.
Results
Of 22 120 patients in the database, 310 with microinvasive
DCIS were identified. Fifty-three were excluded as they
did not undergo axillary surgery, and the remaining 257
patients (82⋅9 per cent) with microinvasive breast cancer
who had axillary staging by SLNB were included in the
analysis. Of these 257 women, 161 (62⋅6 per cent) had only
one SLN, 57 (22⋅2 per cent) had two SLNs, 26 (10⋅1 per
cent) had three SLNs and 13 patients (5⋅1 per cent) had
more than three SLNs removed.
Sentinel node metastasis and tumour
characteristics
Negative SLNs were found in 226 of the 257 women (87⋅9
per cent). In one of these 226 patients, axillary dissection
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Table 1 Literature review of selected studies of microinvasive ductal carcinoma in situ in patients who had sentinel lymph node biopsy
Type of metastasis
(AJCC criteria)
Reference Year
Total no. of
patients with
axillary
staging
Patients
submitted
to SLNB ITCs Micro Macro
SLNB
positivity
(%)
Without defined SLNB status
Cox et al.11 2001 15 15 n.s. n.s. n.s. 3 (20)
Camp et al.10 2005 13 13 n.s. n.s. n.s. 2 (15)
Wilkie et al.29 2005 51 51 5 n.s. n.s. 7 (14)
Tunon-de-Lara et al.28 2008 45 45 0 n.s. n.s. 2 (4)
Fortunato et al.12 2008 77 77 n.s. n.s. n.s. 6 (8)
Vieira et al.6 2010 17 14 n.s. n.s. n.s. 1 (6)
Parikh et al 24 2012 46 4 n.s. n.s. n.s. 1 (2)
With defined SLNB status
Zavotsky et al.31 1999 14 14 1 0 1 2 (14)
Klauber-DeMore et al.19 2000 31 31 0 2 1 3 (10)
Intra et al.16 2003 41 41 0 2 2 4 (10)
Katz et al.18 2006 21 21 0 1 1 2(10)
Leidenius et al.21 2006 11 11 1 0 0 1 (9)
Zavagno et al.30 2007 43 43 0 1 3 4 (9)
Gray et al.13 2007 79 77 2 2 2 6 (8)
Guth et al.14 2008 44 20 2 0 3 5 (11)
Sakr et al.27 2008 20 20 0 2 0 2 (10)
Lyons et al.7 2012 112 112 6 5 3 14 (12⋅5)
Ko et al.20 2012 293 180 6 12 4 22 (7⋅5)
Kapoor et al.17 2013 45 31 4 4 1 9 (20)
Margalit et al.22 2013 68 53 4 3 0 7 (10)
Matsen et al.23 2014 414 414 0 26 6 32 (7⋅7)
Hanna et al.15 2014 81 64 2 0 0 2 (2)
Orzalesi et al.4 2016 126 126 10 3 5 18 (14⋅3)
Values in parentheses are percentages. SLNB, sentinel lymph node biopsy; ITC, isolated tumour cell; micro, micrometastases; macro, macrometastases;
n.s., not stated.
was performed owing to micrometastasis in an additional
level 1 lymph node removed at the time when this still was
an institutional criterion for axillary dissection. A total of 31
women presented with metastatic SLNs: 12 with ITCs,
14 with micrometastases and five with macrometastases.
Thus, the overall rate of metastasis in the SLN was 12⋅1
per cent (31 of 257), with macrometastasis in 1⋅9 per
cent, micrometastasis in 5⋅4 per cent and ITCs in 4⋅7 per
cent (Table S1, supporting information). All patients with
metastatic SLNs had ductal histology of the breast cancer.
A higher proportion with positive SLNs were found in
luminal B (31 per cent) and triple-negative (21 per cent)
subtypes compared with other subtypes (Table 2).
Axillary surgery
Axillary dissection was performed in 16 of the 31
women with positive SLNs: one patient with ITCs,
ten with micrometastasis and five with macrometastasis.
The five patients with macrometastasis had no more than
three positive lymph nodes at final histological examina-
tion (pN1a). The remaining 15 women (11 with ITCs
and 4 with micrometastasis of the SLN) were diagnosed
in the later period (from 2004 onwards) and were thus not
subjected to axillary dissection. Table 2 shows the clinical
and pathological characteristics of the women in the study,
according to lymph node status.
Breast surgery
Breast-conserving surgery (BCS) was performed in 166
of the 257 women (64⋅6 per cent); of these, 150 (90⋅4 per
cent) had negative and 16 (9⋅6 per cent) had positive SLNs.
A total of 91 women (35⋅4 per cent) had a mastectomy,
with conservation of the nipple–areola complex and imme-
diate reconstruction in most cases. Of these 91 women, 76
(84 per cent) had negative and 15 (16 per cent) had posi-
tive SLNs. Of the 31 women who had nipple-sparing mas-
tectomy and received intraoperative radiotherapy of the
nipple–areola complex, 27 had negative and four had
positive SLNs.
Adjuvant treatment
Adjuvant endocrine treatment alone was given to 123
of the 257 women (47⋅9 per cent) who underwent
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Table 2 Patient characteristics according to sentinel lymph node status
SLN status*
Negative (n=226) Positive (n=31) P All patients (n= 257)†
Year of surgery 0⋅915
Before 2003 42 (89) 5 (11) 47 (18⋅3)
2003–2006 111 (88⋅1) 15 (11⋅9) 126 (49⋅0)
2007–2010 73 (87) 11 (13) 84 (32⋅7)
Age (years) 0⋅079
<50 91 (82⋅7) 19 (17⋅3) 110 (42⋅8)
50–59 69 (91) 7 (9) 76 (29⋅6)
≥60 66 (93) 5 (7) 71 (27⋅6)
Menopausal status 0⋅030
Premenopausal 99 (83⋅2) 20 (16⋅8) 119 (46⋅3)
Postmenopausal 127 (92⋅0) 11 (8⋅0) 138 (53⋅7)
Histology 0⋅177
Ductal 203 (86⋅8) 31 (13⋅2) 234 (91⋅1)
Lobular 8 (100) 0 (0) 8 (3⋅1)
Other 15 (100) 0 (0) 15 (5⋅8)
Grade 0⋅511
G1 36 (88) 5 (12) 41 (16⋅0)
G2 87 (90) 10 (10) 97 (37⋅7)
G3 83 (85) 15 (15) 98 (38⋅1)
Unknown 20 (95) 1 (5) 21 (8⋅2)
Subtype 0⋅387
Unknown 23 (88) 3 (12) 26 (10⋅1)
Luminal A 70 (91) 7 (9) 77 (30⋅0)
Luminal B (Ki67≥20%) 22 (81) 5 (19) 27 (10⋅5)
Luminal B (HER2-positive) 22 (88) 3 (12) 25 (9⋅7)
HER2-positive 66 (90) 7 (10) 73 (28⋅4)
Triple negative 23 (79) 6 (21) 29 (11⋅3)
Local treatment 0⋅206
Mastectomy without radiotherapy 49 (82) 11 (18) 60 (23⋅3)
Mastectomy with radiotherapy 27 (87) 4 (13) 31 (12⋅1)
Quadrantectomy with radiotherapy 150 (90⋅4) 16 (9⋅6) 166 (64⋅6)
Systemic treatment <0⋅001
None 109 (93⋅2) 8 (6⋅8) 117 (45⋅5)
Endocrine therapy 110 (89⋅4) 13 (10⋅6) 123 (47⋅9)
Chemotherapy 5 (36) 9 (64) 14 (5⋅4)
Chemotherapy + endocrine therapy 2 (67) 1 (33) 3 (1⋅2)
Values in parentheses are percentages of *row and. †column. SLN, sentinel lymph node; HER2, human epidermal growth factor receptor 2.
SLNB; 14 (5⋅4 per cent) received chemotherapy alone
and three women (1⋅2 per cent) had both chemother-
apy and endocrine therapy (Table 2). The distribution of
treatment by SLN status is shown in Table S1 (supporting
information).
Of the 53 women who did not undergo SLNB, 21
received endocrine therapy alone eight classified as having
luminal A subtype. Four received chemotherapy alone:
one luminal B subtype with Ki67 of 20 per cent or above,
one patient had HER2+ cancer, one triple-negative
subtype, and in one patient information to determine
tumour subtype was missing. Five patients received
endocrine therapy plus chemotherapy: two luminal A,
one luminal B (HER2+), one triple-negative subtype,
and one patient with insufficient information to ascertain
the tumour subtype. The remaining 23 patients did not
receive adjuvant treatment in accordance with pathological
tumour stage.
Recurrence and survival
The median duration of follow-up was 11 years, with 2765
cumulative person-years. At median follow-up, 14 deaths
and 69 first events were observed. Seventeen local recur-
rences, six regional recurrences and six distant metastases
were observed among the 226 SLN-negative patients. In
the SLN-positive group without further axillary dissection,
two local events, one regional event and one case of distant
metastasis were observed, whereas in the SLN-positive
group that had subsequent axillary dissection, there were
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Fig. 1 Cumulative incidence of local, regional and distant events, disease-free and overall survival
a Local, regional and distant events, b disease-free survival and c overall survival.
two local events and one case of distant metastasis. Fig. 1a
shows the cumulative incidence of events over 15 years of
follow-up. The estimated 10-year cumulative incidence of
local, regional and distant recurrence was 7⋅0, 2⋅9 and 3⋅2
per cent respectively. DFS and OS are shown in Fig. 1b
and 1c respectively. The estimated 10-year DFS rate was
77⋅5 per cent, and the estimated 10-year OS rate was 94⋅8
per cent. The cumulative incidence of regional and local
recurrence in relation to SLN status and its associated
surgical axillary treatment (SLN-negative or SLN-positive
followed or not by axillary dissection) is shown
in Fig. 2a,b.
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Fig. 2 Cumulative incidence of regional and local events according to sentinel lymph node status and axillary dissection
a Regional events, b local events. SLN, sentinel lymph node. a P= 0⋅495, b P= 0⋅628 (Gray’s test).
Discussion
In the present study, the incidence of SLNBmetastasis was
12⋅1 per cent in patients with microinvasive breast can-
cer, which falls within the range described in the literature.
The rate of macrometastasis was low (1⋅9 per cent). More-
over the long-term outcomes were favourable (median
follow-up 11 years) with a very low rate of regional recur-
rence in patients with positive SLNs. There was only one
regional recurrence among patients with positive SLNs
who did not undergo axillary dissection, which was not sig-
nificantly different from recurrence in the group of patients
who had axillary dissection after a positive SLNB finding.
No correlation was found between the incidence of SLN
metastasis and type of breast surgery, conservation of the
breast with or without radiotherapy, or mastectomy with-
out radiotherapy. Most interesting is the discovery of a
higher rate of regional recurrence in patients with microin-
vasiveDCISwith negative SLNs, but with a specificmolec-
ular pattern.
The findings of this study indicate that SLNB may not
be useful in microinvasive DCIS owing to the low risk
of lymph node metastasis and good prognosis. The good
prognosis may be explained by the theory15 that the major
rate of positivity could correspond to an iatrogenic tran-
sit of tumour/epithelial cells to lymph nodes, without the
significance of real metastasis. Level 1 evidence shows
that, in patients with SLN-positive breast cancer, axillary
dissection may be avoided when there is a low axillary
metastatic burden (Z0011)42 and in patients undergoing
BCS with radiotherapy; this also supports the conclu-
sion that SLNB in microinvasive DCIS may not be use-
ful. In particular, in the women in the present study who
underwent BCS and axillary dissection for positive sen-
tinel nodes, the total number of positive nodes, includ-
ing sentinel nodes, was less than three, including those
womenwhomet the American College of SurgeonsOncol-
ogy Group Z0011 criteria. An important consideration in
staging the axilla in these patients is the possible implica-
tion for systemic therapy. In this study, however, adjuvant
treatment was largely decided based on cancer biology.
Microinvasive breast cancer is a rare form of breast cancer
defined by the presence of 1mm of invasive cancer in a
background of DCIS, and comprises 0⋅6–3⋅4 per cent of
all breast cancer1,39,41. In the AJCC staging system, it is
considered a subset of T1 disease (T1mi)39. A precise and
more complete definition is the WHO classification of
clearly separate microscopic foci of infiltration of tumour
cells into the mammary stroma, each 1mm or less in size.
No further extension beyond the specialized intralobular
stroma is required, the number of invasive foci and their
proportion among all the carcinoma cells are irrelevant,
and sizes of different foci are not to be added together43.
Invasive cells are generally found in the context of DCIS
in the background with microinvasive cancer found in
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10–20 per cent of patients with DCIS2. This consideration
could justify the fact that it is often defined as DCIS with
microinvasion7,44. The sole presence of an invasive breast
carcinoma of 1mm or less, with no in situ background, is
rare and should be regarded as an invasive carcinoma of
that specific diameter1.
A number of relevant studies6,22,24,45–47 have investigated
the histopathological characteristics and clinical outcomes
of microinvasive DCIS; how patient survival and the bio-
logical behaviour of this rare form of breast carcinoma dif-
fer from DCIS remain controversial. Microinvasive DCIS
is frequently found in a high nuclear grade comedo DCIS
setting, and less frequently with other types of DCIS or
lobular carcinoma in situ48.
The present findings, of low positive SLN rates in
women with good DFS and OS, and the lack of influ-
ence on selection of adjuvant treatment, are in line with
other studies4,7,15,20,23 showing that SLNB inmicroinvasive
DCIS may not be useful. This study supports the evidence
that less surgery, combined with adequate presurgical clini-
cal/histological information allowing the planning of a cor-
rect, personalized, clinical pathway for each patient, may
provide the same level of OS with better patient quality
of life.
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